Trial intelligence / Profile preview

Phase 3 study of asciminib vs bosutinib in CML-CP after ≥2 prior TKIs

2016-002461-66Phase 3Completed

Sponsor

Novartis

Start

Jul 2017

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1